Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

"For patients living with GPP, their flares can be difficult to manage physically and emotionally," said Jensen Yeung, MD, FRCPC, dermatologist in Toronto, Ontario. "As a physician, it has been ...

"For patients living with GPP, their flares can be difficult to manage physically and emotionally," said Jensen Yeung, MD, FRCPC, dermatologist in Toronto, Ontario. "As a physician, it has been ...

Plus, news about Madrona and Ab­dera: Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics … ...

While the UN Global Compact logo is for use by our initiative only, we encourage participants in good standing to use the Endorser "We Support" logo. It can be used, for example, on websites and ...